Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally [Yahoo! Finance]
Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)